Granulicatella Adiacens: Characteristics, Diagnosis, and Treatment Strategies

Granulicatella adiacens is a Gram-positive bacterium that lives quietly in the human mouth and gut but can cause serious, hard-to-diagnose infections when it reaches the bloodstream. It belongs to a group historically called nutritionally variant streptococci (NVS), so named because these organisms refuse to grow on standard laboratory media without help from specific nutrients. That nutritional pickiness makes G. adiacens easy to miss in culture, which means infections are probably underreported. When it does cause disease, endocarditis is the most recognized and most dangerous presentation, though the organism has been found in bone infections, prosthetic device infections, brain abscesses, and more.

What G. Adiacens Is and Where It Came From

For decades, organisms like G. adiacens were lumped together under the umbrella of “nutritionally variant streptococci” and later placed into the genus Abiotrophia. That changed in 2000, when genetic analysis of the 16S ribosomal RNA gene showed that the genus Abiotrophia was not a single coherent group. The organisms clustered into two distinct evolutionary lines: one centered on Abiotrophia defectiva and the other containing the species adiacens, elegans, and balaenopterae. Researchers proposed a new genus, Granulicatella, for the second cluster, formally renaming the species Granulicatella adiacens.¹

The distinction between G. adiacens and A. defectiva is more than a naming exercise. These two species behave differently in the lab, attach to different host tissues, and respond differently to antibiotics. Treating them interchangeably can lead to the wrong antibiotic choice, which makes the taxonomic split clinically relevant.

A Normal Resident of the Mouth and Gut

G. adiacens is a commensal, meaning it typically coexists with the human body without causing harm. It is found in the oral cavity and the gastrointestinal tract, forming part of the normal microbial community.² As a mouth-dwelling organism, it has an obvious route into the bloodstream: any breach of the oral mucosa, from dental procedures to routine brushing over inflamed gums, can allow it access. One reported case of prosthetic hip joint infection developed shortly after a root canal procedure, and investigators concluded the most likely explanation was blood-borne spread of oral bacteria during the dental work.³

Because it is a normal part of the oral flora, a single positive culture does not automatically mean disease. Clinicians have to weigh the clinical picture, the number of positive blood culture bottles, and imaging findings before concluding that G. adiacens is the culprit rather than a contaminant.

How It Causes Trouble

The jump from harmless mouth resident to dangerous pathogen depends on the bacterium’s ability to stick to host tissues. G. adiacens produces a surface protein called Cha that binds to fibronectin, a structural protein found on heart valves and in connective tissues throughout the body. Lab experiments showed that recombinant Cha protein attached to fibronectin and partially blocked G. adiacens from binding, confirming that Cha plays a central role in adhesion.⁴

Interestingly, the adhesion profile of G. adiacens differs from its close relative A. defectiva. G. adiacens binds more readily to saliva-coated surfaces (mimicking the oral environment) and can form biofilms on smooth surfaces, while A. defectiva attaches more strongly to endothelial cells and fibronectin directly. Those different binding preferences suggest that each species may exploit a slightly different niche, and they may follow different routes to causing endocarditis.⁵

Beyond adhesion, G. adiacens triggers a notable inflammatory response. When human immune cells were exposed to proteins secreted by the bacterium, they released high levels of inflammatory signaling molecules, particularly IL-1β and MCP-1, along with TNF-α and several chemokines that recruit more immune cells to the site of infection.⁶ That inflammatory cascade helps explain why NVS endocarditis tends to cause more tissue destruction than you might expect from an organism that grows so reluctantly in the lab.

Endocarditis, the Signature Infection

G. adiacens is best known for causing infective endocarditis, an infection of the heart valve lining. With automated blood culture systems, NVS organisms collectively account for roughly five to six percent of endocarditis cases.⁷ That number may sound small, but NVS endocarditis has long been recognized as carrying higher rates of complications and treatment failure compared to endocarditis caused by ordinary streptococci.

The clinical picture often follows a slower, more indolent course than classic endocarditis. Patients may present with vague symptoms like fatigue, low-grade fever, and weight loss over weeks before a diagnosis is reached. One published case described a patient who developed vegetations on both the mitral and aortic valves, eventually progressing to severe heart failure with mitral regurgitation, aortic insufficiency, and pulmonary hypertension.⁸ The involvement of multiple valves simultaneously is not unique to G. adiacens, but the delayed diagnosis typical of NVS infections gives the disease more time to spread.

Prosthetic heart valves are also vulnerable. In one case, a patient with a bioprosthetic aortic valve presented with headache and transient right-sided weakness, suggesting embolic stroke. Blood cultures eventually grew G. adiacens, and the patient required re-operative valve surgery after the infection recurred despite initial antibiotic treatment.⁹ A comparison of NVS endocarditis with viridans group streptococcal endocarditis found that the rate of in-hospital surgery was roughly similar between the two groups, with about half of NVS endocarditis patients requiring surgical intervention during the same admission.¹⁰

Infections Beyond the Heart

While endocarditis and bloodstream infections dominate the literature, G. adiacens can show up in unexpected places. A growing number of case reports document bone and joint infections that are challenging to diagnose and treat. The organism has been identified as a cause of vertebral osteomyelitis, with a literature review identifying nine previously described cases of G. adiacens vertebral bone infection.¹¹ A more recent report described the first known case of hip osteomyelitis attributed to the organism.¹²

Septic arthritis is another documented but rare manifestation. In one case, a patient had knee pain and swelling evaluated by arthrocentesis and arthroscopy with no organism identified. Her symptoms improved briefly on antibiotics but returned three months later. Only when synovial fluid was inoculated directly into blood culture bottles was G. adiacens recovered.¹³ That case illustrates a recurring theme: the organism’s growth requirements make it invisible to standard culture approaches, and clinicians often need to think creatively about sample processing to catch it.

The range of reported infections also includes pulmonary infections, brain abscesses, gastrointestinal sepsis, and infections of implanted medical devices.¹⁴ An arteriovenous graft infection was documented as the first of its kind, adding to the list of devices and prosthetic materials that G. adiacens can colonize.¹⁵

Pediatric Infections

G. adiacens infections are not limited to adults. A retrospective study at a single children’s hospital identified seven pediatric cases over the study period. Three of those children had bloodstream infections, two had central line-related infections, one had bacteremia with pneumonia, and one had infective endocarditis. Notably, all seven patients survived.¹⁶ Four of the infections were community-acquired and three were healthcare-associated, reinforcing the point that these infections can arise both inside and outside the hospital setting. The small number of published pediatric cases makes it hard to draw firm conclusions about how children differ from adults in terms of disease severity, but the survival of all patients in that series is encouraging.

Why It Is So Hard to Diagnose

The single biggest obstacle to diagnosing G. adiacens infections is the organism’s refusal to grow without supplementation. It requires pyridoxal (a form of vitamin B6) or the presence of helper bacteria to grow on agar plates. On a standard blood agar plate, G. adiacens colonies may appear as tiny satellite growths near colonies of other bacteria, or they may not appear at all. In automated blood culture systems, the bottles typically contain enough nutrients for the organism to grow and trigger a positive signal, but subculture onto standard plates can fail. When subcultures are negative but the blood culture bottle flagged positive, the lab may report “no growth on subculture,” and clinicians may dismiss the result as a false positive or contamination.

The septic arthritis case mentioned earlier is a good example of how diagnosis can be rescued by adjusting technique: inoculating clinical fluid directly into enriched blood culture bottles rather than plating it on standard agar.¹³ When conventional culture fails and there is clinical suspicion of a fastidious organism, this approach and the use of supplemented media (such as agar with added pyridoxal or thiol-containing compounds) can make the difference.

Even when the organism does grow, identifying it correctly with conventional biochemical methods is unreliable. Two modern technologies have changed the game. MALDI-TOF mass spectrometry, which identifies bacteria by their protein fingerprint, performed well in a head-to-head comparison. One system correctly identified all 14 tested NVS isolates, including 10 G. adiacens strains, on the first attempt. A second system correctly identified most G. adiacens isolates initially and all of them on repeat testing.¹⁷ 16S ribosomal RNA gene sequencing remains the gold-standard reference method and was used alongside MALDI-TOF in the largest susceptibility studies to confirm species-level identification.¹⁸

Antibiotic Susceptibility Is Not What You Might Expect

Because G. adiacens was historically grouped with streptococci, many clinicians assume it will respond to the same antibiotics, particularly penicillin and ceftriaxone. The reality is more complicated, and this is arguably the most clinically important thing to know about the organism. In a study of 109 G. adiacens isolates tested by broth microdilution, only about a third were susceptible to penicillin. Ceftriaxone fared even worse, with just over a fifth of isolates testing susceptible. Cefotaxime susceptibility was a dismal ten percent, and cefepime was essentially useless at three percent. Even among the subset of G. adiacens isolates that tested susceptible to penicillin, nearly two-thirds were nonsusceptible to ceftriaxone.¹⁹

Those numbers contrast sharply with A. defectiva, for which penicillin susceptibility was similar (about a quarter of isolates) but ceftriaxone worked well at over ninety percent. This is exactly why lumping the two species together for treatment purposes is a mistake.

The bright spots in the susceptibility data for G. adiacens are vancomycin, to which all tested isolates were susceptible, levofloxacin (susceptible in about ninety-seven percent), and meropenem (roughly eighty-seven percent). Clindamycin also performed reasonably well at eighty percent susceptibility.¹⁹

Treatment Strategies in Practice

For endocarditis specifically, guidelines have historically recommended treating NVS infections as if they were enterococcal endocarditis, using combination therapy with a cell-wall active agent plus an aminoglycoside like gentamicin. The logic was that NVS organisms tolerate beta-lactam monotherapy poorly, and adding gentamicin provides synergistic killing. However, the susceptibility data above raise serious questions about using penicillin or ceftriaxone as the cell-wall agent for G. adiacens.

Given that vancomycin susceptibility is essentially universal, many infectious disease specialists now prefer vancomycin as the backbone for empiric therapy once G. adiacens is identified, particularly in endocarditis or other severe infections where treatment failure carries high stakes. The addition of gentamicin for the initial phase of endocarditis treatment follows the pattern used for enterococcal endocarditis and remains a common approach, though evidence for or against it in NVS endocarditis is largely extrapolated rather than tested in controlled trials.

For less severe infections like septic arthritis or osteomyelitis, where prolonged therapy is needed, options like levofloxacin or meropenem may be used based on susceptibility testing. The key practical point is that clinicians should not assume the standard streptococcal endocarditis regimen of penicillin or ceftriaxone plus gentamicin will work for G. adiacens. Susceptibility testing matters here more than it does for many other streptococcus-like organisms, and labs need to be told what they are looking for so they can set up appropriate testing conditions.

The rate of relapse and treatment failure with NVS endocarditis has historically been reported as higher than for ordinary streptococcal endocarditis, and the bioprosthetic valve case described earlier is a real-world example of that pattern, with blood cultures turning positive again after what appeared to be adequate initial treatment.⁹ When relapse occurs, surgical intervention to remove infected tissue or replace a valve is often necessary.

The Dental Procedure Connection

Because G. adiacens is part of the normal oral flora, procedures that disrupt the gum line represent an obvious entry point. The connection between dental work and prosthetic joint infections by oral organisms is well documented across multiple species, and G. adiacens fits the same pattern. One patient developed a prosthetic hip infection shortly after root canal treatment, with timing and organism identity pointing toward transient bacteremia during the dental procedure as the source.³

Whether prophylactic antibiotics before dental procedures would prevent G. adiacens infections in patients with prosthetic valves or joints is a matter of ongoing debate in infectious disease and cardiology guidelines. Current recommendations generally support antibiotic prophylaxis before certain dental procedures for patients with prosthetic heart valves or a history of endocarditis, but the evidence base is observational rather than from randomized trials. The G. adiacens angle adds a wrinkle: if your prophylactic regimen is amoxicillin (a beta-lactam), and roughly two-thirds of G. adiacens strains are not susceptible to penicillin, the protection may be incomplete for this particular organism.

Prosthetic and Medical Device Infections

Implanted materials give G. adiacens something extra to work with. The organism’s ability to form biofilms on smooth surfaces, as demonstrated in laboratory experiments, is relevant any time foreign material is present in the body.⁵ Biofilm-embedded bacteria are notoriously harder to kill with antibiotics alone because the biofilm matrix physically shields cells from drug exposure and slows bacterial metabolism, rendering growth-dependent antibiotics less effective.

Reported device-related infections include prosthetic heart valves, prosthetic joints, and an arteriovenous graft used for dialysis access.¹⁵ In most of these cases, medical or surgical removal of the device was ultimately required, consistent with the general principle that biofilm infections on hardware are difficult to cure with antibiotics alone. For patients with prosthetic devices who develop unexplained fevers or signs of infection, and whose initial cultures are negative, G. adiacens should be on the differential, and supplemented culture media or molecular testing should be considered.

An Organism Likely Underrecognized

Much of what makes G. adiacens medically frustrating circles back to how easily it can slip through diagnostic cracks. A lab that does not add pyridoxal to subculture media may never grow it. A clinician who sees “gram-positive cocci in chains” in the blood culture Gram stain may assume viridans streptococcus and prescribe ceftriaxone, only to see treatment fail weeks later. Hospitals that have adopted MALDI-TOF identification have a clear advantage: the technology identifies the organism rapidly and accurately, removing the guesswork of traditional biochemical testing.¹⁷ As more labs adopt this technology and clinicians become aware of the unique susceptibility profile, the proportion of G. adiacens infections recognized and treated correctly should improve. For now, it remains an organism that rewards suspicion and punishes assumption.